BioSpace News Archive

EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions based on its unique non-replicative HSV-1 vector platform, announced the appointment of Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics and participating key opinion leaders for its Investor R&D Day.

Renalytix plc announces the publication of new real-world evidence in Primary Care and Community Health demonstrating the Company’s KidneyIntelX bioprognostic™ test resulted in changed clinical decision making for patients in the early-stage of diabetic kidney disease being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs.

Trevena, Inc. announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550.

PolyPid Ltd. today announced that Phase 2 clinical data for D-PLEX 100 will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.

BiondVax announced today statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy.

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be difficult to reach with surgery and other treatments.

Tetra Bio-Pharma Inc. today announced the filing of three patent applications for its novel therapeutic, ARDS-003.

Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).

Industry experts in anti-aging and functional medicine will be meeting in Las Vegas this December, along with thousands of attendees from across the globe for Longevity Fest: the 30th Annual World Congress hosted by the Academy of Anti-Aging Medicine (A4M) on December 9th - 11th.